肝内胆管癌外科治疗的若干问题

司安锋; 雷正清; 程张军

doi:10.12449/JCH241202

肝内胆管癌外科治疗的若干问题

DOI: 10.12449/JCH241202

1.
东部战区总医院普通外科，南京 210002
2.
东南大学附属中大医院肝胆胰中心，南京 210009

基金项目:

国家自然科学基金面上项目 (81871988);

国家自然科学基金青年科学基金项目 (82103009)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：司安锋负责课题设计，文献检索，资料分析，撰写论文；雷正清参与收集数据，文献检索，资料分析，修改论文；程张军负责课题设计，拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
程张军， chengzhangjun@seu.edu.cn （ORCID： 0000-0001-6500-7535）

计量
- 文章访问数: 118
- HTML全文浏览量: 2051
- PDF下载量: 86
- 被引次数: 0
出版历程
- 收稿日期: 2024-08-31
- 录用日期: 2024-10-03
- 出版日期: 2024-12-25

Several issues in the surgical treatment of intrahepatic cholangiocarcinoma

1.
Department of General Surgery，General Hospital of Eastern Theater Command，Nanjing 210002，China
2.
Hepatobiliary and Pancreatic Center，Zhongda Hospital Affiliated to Southeast University，Nanjing 210009，China

Research funding:

General Project of National Natural Science Foundation of China (81871988);

National Natural Science Foundation of China Young Scientist Fund (82103009)

More Information

Corresponding author: CHENG Zhangjun， chengzhangjun@seu.edu.cn （ORCID： 0000-0001-6500-7535）

摘要

摘要: 肝内胆管癌（ICC）在肝脏恶性肿瘤中发病率居第二位，恶性程度高、预后差。手术治疗目前仍是ICC可能获得治愈的唯一手段，但其R0切除率相对较低、术后无复发生存时间短。合理的切缘宽度、解剖性肝切除的价值、淋巴结清扫的地位以及腹腔镜肝切除和肝移植的肿瘤学效果等诸多问题仍有待厘清。本文旨在讨论ICC外科治疗策略的相关研究进展和存在的争议，以期为临床治疗决策提供参考。
- 胆管上皮癌 /
- 外科手术 /
- 治疗学
Abstract: Intrahepatic cholangiocarcinoma （ICC） ranks second among malignant liver tumors and has high malignancy and poor prognosis. Currently， surgical treatment remains the only potentially curative therapy for ICC， but with a relatively low R0 resection rate and a short recurrence-free survival time after surgery. There are still several issues that need to be clarified， such as reasonable margin width， the value of anatomical hepatectomy， the role of lymph node dissection， and the oncological efficacy of laparoscopic liver resection and liver transplantation. This article reviews the research advances in surgical treatment strategies for ICC and related controversies， in order to provide a reference for clinical decision-making.
- Cholangiocarcinoma /
- Surgical Procedures， Operative /
- Therapeutics

HTML全文

参考文献(67)

[1]	SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72( 1): 7- 33. DOI: 10.3322/caac.21708.
[2]	SAHA SK, ZHU AX, FUCHS CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise[J]. Oncologist, 2016, 21( 5): 594- 599. DOI: 10.1634/theoncologist.2015-0446.
[3]	ENDO I, GONEN M, YOPP AC, et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection[J]. Ann Surg, 2008, 248( 1): 84- 96. DOI: 10.1097/SLA.0b013e318176c4d3.
[4]	EDGE SB, COMPTON CC. The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17( 6): 1471- 1474. DOI: 10.1245/s10434-010-0985-4.
[5]	WANG YZ, LI J, XIA Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31( 9): 1188- 1195. DOI: 10.1200/JCO.2012.41.5984.
[6]	AMIN MB ES, GREENE F. AJCC Cancer Staging Manual[M]. 8^th ed. New York: Springer International Publishing, 2017: 295- 302.
[7]	KANG SH, HWANG S, LEE YJ, et al. Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2018, 25( 4): 240- 248. DOI: 10.1002/jhbp.543.
[8]	CHENG ZJ, LEI ZQ, SI AF, et al. Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers[J]. HPB(Oxford), 2019, 21( 12): 1656- 1666. DOI: 10.1016/j.hpb.2019.05.010.
[9]	LI ZZ, YUAN L, ZHANG C, et al. A novel prognostic scoring system of intrahepatic cholangiocarcinoma with machine learning basing on real-world data[J]. Front Oncol, 2021, 10: 576901. DOI: 10.3389/fonc.2020.576901.
[10]	CHEN X, DONG LQ, CHEN L, et al. Epigenome-wide development and validation of a prognostic methylation score in intrahepatic cholangiocarcinoma based on machine learning strategies[J]. Hepatobiliary Surg Nutr, 2023, 12( 4): 478- 494. DOI: 10.21037/hbsn-21-424.
[11]	LIU YG, JIANG ST, ZHANG JW, et al. Development and validation of web-based nomograms for predicting survival status in patients with intrahepatic cholangiocarcinoma depending on the surgical status: A SEER database analysis[J]. Sci Rep, 2024, 14( 1): 1568. DOI: 10.1038/s41598-024-52025-3.
[12]	Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group. Chinese expert consensus on management of intrahepatic cholangiocarcinoma(2022 edition)[J]. Chin J Dig Surg, 2022, 21( 10): 1269- 1301. DOI: 10.3760/cma.j.cn115610-20220829-00476. 中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21( 10): 1269- 1301. DOI: 10.3760/cma.j.cn115610-20220829-00476.
[13]	SI AF, LI J, YANG ZS, et al. Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2019, 26( 6): 1841- 1850. DOI: 10.1245/s10434-019-07260-8.
[14]	National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508. 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
[15]	IMAMURA H, SANO K, SUGAWARA Y, et al. Assessment of hepatic reserve for indication of hepatic resection: Decision tree incorporating indocyanine green test[J]. J Hepatobiliary Pancreat Surg, 2005, 12( 1): 16- 22. DOI: 10.1007/s00534-004-0965-9.
[16]	SHINDOH J, TZENG CW, ALOIA TA, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases[J]. Ann Surg Oncol, 2013, 20( 8): 2493- 2500. DOI: 10.1245/s10434-012-2864-7.
[17]	BOZKURT E, SIJBERDEN JP, KASAI MD, et al. Efficacy and perioperative safety of different future liver remnant modulation techniques: A systematic review and network meta-analysis[J]. HPB(Oxford), 2024, 26( 4): 465- 475. DOI: 10.1016/j.hpb.2024.01.002.
[18]	HWANG S, LEE SG, KO GY, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy[J]. Ann Surg, 2009, 249( 4): 608- 616. DOI: 10.1097/SLA.0b013e31819ecc5c.
[19]	LE ROY B, GALLON A, CAUCHY F, et al. Combined biembolization induces higher hypertrophy than portal vein embolization before major liver resection[J]. HPB(Oxford), 2020, 22( 2): 298- 305. DOI: 10.1016/j.hpb.2019.08.005.
[20]	CHEBARO A, BUC E, DURIN T, et al. Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy?: A retrospective multicentric study[J]. Ann Surg, 2021, 274( 5): 874- 880. DOI: 10.1097/SLA.0000000000005121.
[21]	LI PP, HUANG G, JIA NY, et al. Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: A randomized comparative study[J]. Hepatobiliary Surg Nutr, 2022, 11( 1): 38- 51. DOI: 10.21037/hbsn-20-264.
[22]	LI J, MOUSTAFA M, LINECKER M, et al. ALPPS for locally advanced intrahepatic cholangiocarcinoma: Did aggressive surgery lead to the oncological benefit? An international multi-center study[J]. Ann Surg Oncol, 2020, 27( 5): 1372- 1384. DOI: 10.1245/s10434-019-08192-z.
[23]	MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73( 2): 198- 222. DOI: 10.3322/caac.21759.
[24]	WEBER SM, RIBERO D, O’REILLY EM, et al. Intrahepatic cholangiocarcinoma: Expert consensus statement[J]. HPB(Oxford), 2015, 17( 8): 669- 680. DOI: 10.1111/hpb.12441.
[25]	NAM K, HWANG DW, SHIM JH, et al. Novel preoperative nomogram for prediction of futile resection in patients undergoing exploration for potentially resectable intrahepatic cholangiocarcinoma[J]. Sci Rep, 2017, 7: 42954. DOI: 10.1038/srep42954.
[26]	CHU HP, LIU ZL, LIANG W, et al. Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma[J]. Eur Radiol, 2021, 31( 4): 2368- 2376. DOI: 10.1007/s00330-020-07250-5.
[27]	RATTI F, CASADEI-GARDINI A, CIPRIANI F, et al. Laparoscopic surgery for intrahepatic cholangiocarcinoma: A focus on oncological outcomes[J]. J Clin Med, 2021, 10( 13): 2828. DOI: 10.3390/jcm10132828.
[28]	FARGES O, FUKS D, BOLESLAWSKI E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: A multicenter study by the AFC-IHCC-2009 study group[J]. Ann Surg, 2011, 254( 5): 824- 829. DOI: 10.1097/SLA.0b013e318236c21d.
[29]	SPOLVERATO G, YAKOOB MY, KIM Y, et al. The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22( 12): 4020- 4028. DOI: 10.1245/s10434-015-4472-9.
[30]	JIANG JH, FANG DZ, HU YT. Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J]. BMJ Open, 2023, 13( 5): e067222. DOI: 10.1136/bmjopen-2022-067222.
[31]	ZHANG XF, BAGANTE F, CHAKEDIS J, et al. Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: Impact of major versus minor hepatectomy[J]. J Gastrointest Surg, 2017, 21( 11): 1841- 1850. DOI: 10.1007/s11605-017-3499-6.
[32]	MURAKAMI S, AJIKI T, OKAZAKI T, et al. Factors affecting survival after resection of intrahepatic cholangiocarcinoma[J]. Surg Today, 2014, 44( 10): 1847- 1854. DOI: 10.1007/s00595-013-0825-9.
[33]	ENDO Y, SASAKI K, MOAZZAM Z, et al. Higher tumor burden status dictates the impact of surgical margin status on overall survival in patients undergoing resection of intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2023, 30( 4): 2023- 2032. DOI: 10.1245/s10434-022-12803-7.
[34]	LIU HZ, LIN ZG, HUANG JL, et al. Effect of surgical margin width on prognosis in patients with single intrahepatic cholangiocarcinoma from a multicenter study[J]. J Surg Concepts Pract, 2021, 26( 2): 130- 137. DOI: 10.16139/j.1007-9610.2021.02.009. 刘红枝, 林自国, 黄建龙, 等. 切缘宽度对单发肝内胆管癌预后影响的多中心研究[J]. 外科理论与实践, 2021, 26( 2): 130- 137. DOI: 10.16139/j.1007-9610.2021.02.009.
[35]	ALAIMO L, MOAZZAM Z, ENDO Y, et al. The application of artificial intelligence to investigate long-term outcomes and assess optimal margin width in hepatectomy for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2023, 30( 7): 4292- 4301. DOI: 10.1245/s10434-023-13349-y.
[36]	SHINDOH J, MAKUUCHI M, MATSUYAMA Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma[J]. J Hepatol, 2016, 64( 3): 594- 600. DOI: 10.1016/j.jhep.2015.10.015.
[37]	WU JY, HUANG WT, HE WB, et al. Long-term outcomes of anatomic vs. non-anatomic resection in intrahepatic cholangiocarcinoma with hepatolithiasis: A multicenter retrospective study[J]. Front Med(Lausanne), 2023, 10: 1130692. DOI: 10.3389/fmed.2023.1130692.
[38]	WANG C, CIREN PC, DANZENG AW, et al. Anatomical resection improved the outcome of intrahepatic cholangiocarcinoma: A propensity score matching analysis of a retrospective cohort[J]. J Oncol, 2022, 2022: 4446243. DOI: 10.1155/2022/4446243.
[39]	KE Q, WANG L, LIN ZG, et al. Anatomic versus non-anatomic resection for early-stage intrahepatic cholangiocarcinoma: A propensity score matching and stabilized inverse probability of treatment weighting analysis[J]. BMC Cancer, 2023, 23( 1): 850. DOI: 10.1186/s12885-023-11341-z.
[40]	de JONG MC, NATHAN H, SOTIROPOULOS GC, et al. Intrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol, 2011, 29( 23): 3140- 3145. DOI: 10.1200/JCO.2011.35.6519.
[41]	SPOSITO C, DROZ DIT BUSSET M, VIRDIS M, et al. The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review[J]. Eur J Surg Oncol, 2022, 48( 1): 150- 159. DOI: 10.1016/j.ejso.2021.08.009.
[42]	MA WH, LEI ZQ, YU QS, et al. A novel nomogram for individualized preoperative prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma[J]. Chin J Surg, 2022, 60( 4): 363- 371. DOI: 10.3760/cma.j.cn112139-20220105-00008. 马伟虎, 雷正清, 余秋石, 等. 肝内胆管癌淋巴结转移个体化术前预测模型的构建及应用[J]. 中华外科杂志, 2022, 60( 4): 363- 371. DOI: 10.3760/cma.j.cn112139-20220105-00008.
[43]	CHEN C, SU JB, WU H, et al. Prognostic value of lymphadenectomy in node-negative intrahepatic cholangiocarcinoma: A multicenter, retrospectively study[J]. Eur J Surg Oncol, 2023, 49( 4): 780- 787. DOI: 10.1016/j.ejso.2022.11.008.
[44]	SPOSITO C, RATTI F, CUCCHETTI A, et al. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma[J]. J Hepatol, 2023, 78( 2): 356- 363. DOI: 10.1016/j.jhep.2022.10.021.
[45]	KIM SH, HAN DH, CHOI GH, et al. Recommended minimal number of harvested lymph nodes for intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2021, 25( 5): 1164- 1171. DOI: 10.1007/s11605-020-04622-6.
[46]	ZHANG XF, XUE F, DONG DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis[J]. Ann Surg, 2021, 274( 6): e1187- e1195. DOI: 10.1097/SLA.0000000000003788.
[47]	ZHANG R, ZHANG JW, CHEN C, et al. The optimal number of examined lymph nodes for accurate staging of intrahepatic cholangiocarcinoma: A multi-institutional analysis using the nodal staging score model[J]. Eur J Surg Oncol, 2023, 49( 8): 1429- 1435. DOI: 10.1016/j.ejso.2023.03.221.
[48]	BRAUER DG, FIELDS RC, TAN BR Jr, et al. Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma[J]. HPB(Oxford), 2018, 20( 5): 470- 476. DOI: 10.1016/j.hpb.2017.11.010.
[49]	YIN LL, ZHAO S, ZHU HL, et al. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study[J]. Sci Rep, 2021, 11( 1): 12166. DOI: 10.1038/s41598-021-91823-x.
[50]	BUETTNER S, CATE DWG TEN, BAGANTE F, et al. Survival after resection of multiple tumor foci of intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg, 2019, 23( 11): 2239- 2246. DOI: 10.1007/s11605-019-04184-2.
[51]	WRIGHT GP, PERKINS S, JONES H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: A comparison of surgical resection with intra-arterial therapies[J]. Ann Surg Oncol, 2018, 25( 1): 83- 90. DOI: 10.1245/s10434-017-6110-1.
[52]	FRANSSEN S, SOARES KC, JOLISSAINT JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma[J]. JAMA Surg, 2022, 157( 7): 590- 596. DOI: 10.1001/jamasurg.2022.1298.
[53]	REAMES BN, EJAZ A, KOERKAMP BG, et al. Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis[J]. J Surg Oncol, 2017, 116( 2): 133- 139. DOI: 10.1002/jso.24633.
[54]	CONCI S, VIGANÒ L, ERCOLANI G, et al. Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic cholangiocarcinoma[J]. Eur J Surg Oncol, 2020, 46( 9): 1727- 1733. DOI: 10.1016/j.ejso.2020.04.007.
[55]	MABILIA A, MAZZOTTA AD, ROBIN F, et al. R1 vascular or parenchymal margins: What is the impact after resection of intrahepatic cholangiocarcinoma?[J]. Cancers(Basel), 2022, 14( 20): 5151. DOI: 10.3390/cancers14205151.
[56]	HU YF, HU HJ, MA WJ, et al. Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: A systematic review of propensity score-matched studies[J]. Updates Surg, 2023, 75( 8): 2049- 2061. DOI: 10.1007/s13304-023-01648-8.
[57]	HOBEIKA C, CAUCHY F, FUKS D, et al. Laparoscopic versus open resection of intrahepatic cholangiocarcinoma: Nationwide analysis[J]. Br J Surg, 2021, 108( 4): 419- 426. DOI: 10.1093/bjs/znaa110.
[58]	MUNIR MM, DILLHOFF M, TSAI S, et al. Textbook oncologic outcomes among patients undergoing laparoscopic, robotic and open surgery for intrahepatic and perihilar cholangiocarcinoma[J]. HPB(Oxford), 2024, 26( 8): 1051- 1061. DOI: 10.1016/j.hpb.2024.05.010.
[59]	SAPISOCHIN G, RODRÍGUEZ de LOPE C, GASTACA M, et al.“Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?[J]. Am J Transplant, 2014, 14( 3): 660- 667. DOI: 10.1111/ajt.12591.
[60]	SAPISOCHIN G, FACCIUTO M, RUBBIA-BRANDT L, et al. Liver transplantation for"very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64( 4): 1178- 1188. DOI: 10.1002/hep.28744.
[61]	ZIOGAS IA, GIANNIS D, ECONOMOPOULOS KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: A meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105( 10): 2263- 2271. DOI: 10.1097/TP.0000000000003539.
[62]	LUNSFORD KE, JAVLE M, HEYNE K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: A prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3( 5): 337- 348. DOI: 10.1016/S2468-1253(18)30045-1.
[63]	HONG JC, JONES CM, DUFFY JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: A 24-year experience in a single center[J]. Arch Surg, 2011, 146( 6): 683- 689. DOI: 10.1001/archsurg.2011.116.
[64]	ABDELRAHIM M, AL-RAWI H, ESMAIL A, et al. Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: Case-series[J]. Curr Oncol, 2022, 29( 5): 3585- 3594. DOI: 10.3390/curroncol29050290.
[65]	HUANG GB, SONG WL, ZHANG YC, et al. Liver transplantation for intrahepatic cholangiocarcinoma: A propensity score-matched analysis[J]. Sci Rep, 2023, 13( 1): 10630. DOI: 10.1038/s41598-023-37896-2.
[66]	de MARTIN E, RAYAR M, GOLSE N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J]. Liver Transpl, 2020, 26( 6): 785- 798. DOI: 10.1002/lt.25737.
[67]	HUE JJ, ROCHA FG, AMMORI JB, et al. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the national cancer database[J]. J Surg Oncol, 2021, 123( 4): 949- 956. DOI: 10.1002/jso.26370.